Please assess the completion status of the following clinical trial:

Trial Title: PDE-4 Inhibitor Roflumilast and GLP-1 Agonist Liraglutide in Polycystic Ovary Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years old to menopause~* polycystic ovary syndrome (NICHD criteria)~* BMI of 30 kg/m² or higher~Exclusion Criteria:~* depression~* type 1 or type 2 diabetes mellitus~* history of carcinoma~* history of pancreatitis~* Cushing's syndrome or congenital (non-classic) adrenal hyperplasia~* significant cardiovascular, kidney or hepatic disease~* the use of medications other than metformin known or suspected to affect reproductive or metabolic functions~* the use of statins, within 90 days prior to study entry

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- metformin (Type: ACTIVE_COMPARATOR): In the metformin group metformin was initiated at a dose of 500 mg once per day and increased by 500 mg every 3 days up to 2x1000 mg BID per os.
- liraglutide (Type: ACTIVE_COMPARATOR): In the liraglutide group liraglutide was initiated at a dose of 0,6mg sc once per day for one week and increased to 1,2mg sc one per day.
- roflumilast (Type: ACTIVE_COMPARATOR): In the roflumilast group roflumilast was initiated at a dose of 500 mg BID per os.

Based on this trial design, predict the completion outcome and termination type (if applicable).